Stock Rating Downgrade
In recent days the Value Trend Rating for Neurocrine Biosciences Inc (NASDAQ: NBIX) weakened from B to C reflecting eroding fundamentals and low Appreciation Potential.
Recent Price Action
Neurocrine Biosciences Inc (NASDAQ: NBIX) stock declined slightly by -0.4% on 4/19/24. The stock closed at $132.00. However, trading volume in this decline was unusually low at 63% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -2.9% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, NBIX is expected to continue to be a major Value Builder.
Neurocrine Biosciences has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Neurocrine Biosciences has a neutral Appreciation Score of 46 but a good Power Rating of 78, leading to the High Neutral Value Trend Rating.
Be the first to comment